Cargando…
Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report
A 46-year-old man underwent right partial nephrectomy for type 2 papillary renal cell carcinoma (PRCC) in 2011. Lung metastasis and lymph node (LN) metastases around the inferior vena cave appeared in 2012. A right radical nephrectomy and extensive LN dissection was performed and the resection of lu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907800/ https://www.ncbi.nlm.nih.gov/pubmed/33732457 http://dx.doi.org/10.3892/mco.2021.2233 |
_version_ | 1783655571520487424 |
---|---|
author | Arai, Yuichi Kitamura, Yosuke Miyai, Kosuke Hatanaka, Mina Hashimoto, Hirofumi Horiguchi, Akio Ito, Keiichi |
author_facet | Arai, Yuichi Kitamura, Yosuke Miyai, Kosuke Hatanaka, Mina Hashimoto, Hirofumi Horiguchi, Akio Ito, Keiichi |
author_sort | Arai, Yuichi |
collection | PubMed |
description | A 46-year-old man underwent right partial nephrectomy for type 2 papillary renal cell carcinoma (PRCC) in 2011. Lung metastasis and lymph node (LN) metastases around the inferior vena cave appeared in 2012. A right radical nephrectomy and extensive LN dissection was performed and the resection of lung metastasis was performed one month after the nephrectomy. Mediastinal LN metastases occurred in 2013, and resection of the affected LNs was performed. Sunitinib and zoledronic acid was started in 2014 because mediastinal LN swelling and multiple bone metastases appeared. Sunitinib treatment was stopped soon after due to adverse events and axitinib treatment was started. Axitinib was effective and the patient had stable disease for 30 months. Adverse events were successfully controlled by dose reduction and periodic drug withdrawal schedules (for example, 5 days on, 2 days off). Axitinib was further continued for 19 months as the metastatic lesions had progressed slowly. Temsirolimus treatment was started in 2019, but it was stopped after three cycles due to interstitial pneumonia. The patient died 80 months after the initial recurrence. Using multidisciplinary treatment, durable disease control was achieved in a patient with metastatic type 2 PRCC. |
format | Online Article Text |
id | pubmed-7907800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-79078002021-03-16 Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report Arai, Yuichi Kitamura, Yosuke Miyai, Kosuke Hatanaka, Mina Hashimoto, Hirofumi Horiguchi, Akio Ito, Keiichi Mol Clin Oncol Articles A 46-year-old man underwent right partial nephrectomy for type 2 papillary renal cell carcinoma (PRCC) in 2011. Lung metastasis and lymph node (LN) metastases around the inferior vena cave appeared in 2012. A right radical nephrectomy and extensive LN dissection was performed and the resection of lung metastasis was performed one month after the nephrectomy. Mediastinal LN metastases occurred in 2013, and resection of the affected LNs was performed. Sunitinib and zoledronic acid was started in 2014 because mediastinal LN swelling and multiple bone metastases appeared. Sunitinib treatment was stopped soon after due to adverse events and axitinib treatment was started. Axitinib was effective and the patient had stable disease for 30 months. Adverse events were successfully controlled by dose reduction and periodic drug withdrawal schedules (for example, 5 days on, 2 days off). Axitinib was further continued for 19 months as the metastatic lesions had progressed slowly. Temsirolimus treatment was started in 2019, but it was stopped after three cycles due to interstitial pneumonia. The patient died 80 months after the initial recurrence. Using multidisciplinary treatment, durable disease control was achieved in a patient with metastatic type 2 PRCC. D.A. Spandidos 2021-04 2021-02-12 /pmc/articles/PMC7907800/ /pubmed/33732457 http://dx.doi.org/10.3892/mco.2021.2233 Text en Copyright: © Arai et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Arai, Yuichi Kitamura, Yosuke Miyai, Kosuke Hatanaka, Mina Hashimoto, Hirofumi Horiguchi, Akio Ito, Keiichi Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report |
title | Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report |
title_full | Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report |
title_fullStr | Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report |
title_full_unstemmed | Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report |
title_short | Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report |
title_sort | long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: a case report |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907800/ https://www.ncbi.nlm.nih.gov/pubmed/33732457 http://dx.doi.org/10.3892/mco.2021.2233 |
work_keys_str_mv | AT araiyuichi longtermdiseasecontrolofmetastatictype2papillaryrenalcellcarcinomausinglocaltreatmentandmoleculartargetedtherapyacasereport AT kitamurayosuke longtermdiseasecontrolofmetastatictype2papillaryrenalcellcarcinomausinglocaltreatmentandmoleculartargetedtherapyacasereport AT miyaikosuke longtermdiseasecontrolofmetastatictype2papillaryrenalcellcarcinomausinglocaltreatmentandmoleculartargetedtherapyacasereport AT hatanakamina longtermdiseasecontrolofmetastatictype2papillaryrenalcellcarcinomausinglocaltreatmentandmoleculartargetedtherapyacasereport AT hashimotohirofumi longtermdiseasecontrolofmetastatictype2papillaryrenalcellcarcinomausinglocaltreatmentandmoleculartargetedtherapyacasereport AT horiguchiakio longtermdiseasecontrolofmetastatictype2papillaryrenalcellcarcinomausinglocaltreatmentandmoleculartargetedtherapyacasereport AT itokeiichi longtermdiseasecontrolofmetastatictype2papillaryrenalcellcarcinomausinglocaltreatmentandmoleculartargetedtherapyacasereport |